Back

Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study

31 August 2026 (08:30 - 08:45)
Organised by: Logo
Congress Presentation Part of: Beyond statins: the next wave of lipid-lowering therapies Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Dan Zhu

Peking University Third Hospital, Beijing (China)

5 More presentations in this session

Presentation thumbnail
Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
Professor I. Hilgendorf (Berlin, DE)
Presentation thumbnail
Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial
Doctor K. Oyama (Sendai, JP)
Presentation thumbnail
A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)
Doctor Z. Tian (Beijing, CN)
Presentation thumbnail
Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial
Doctor R. Giugliano (Boston, US)
Presentation thumbnail
Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)
Professor S. Nissen (Cleveland, US)

Access the full session

Session thumbnail
Beyond statins: the next wave of lipid-lowering therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 08:30 CET
You may be interested in
thumbnail
Webinar
Lipoprotein(a): current role and future perspectives in cardiovascular medicine
31 October 2025
thumbnail
Congress Presentation
Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)
28 August 2023
thumbnail
Congress Presentation
Patient views on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study
29 August 2025
thumbnail
Congress Presentation
Impact of history of vascular disease on lipoprotein(a) associations with cardiovascular outcomes: a Mendelian randomisation study in 283,658 UK Biobank participants
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources